Assignee: Alexion Pharmaceuticals, Inc.

Location: Cheshire, CT
No. of patents: 29

Number	Title	Issue Date
8075884	Antibodies to OX-2/CD200 and uses thereof This application provides methods and compositions for modulating and/or depleting CD200 positive cells. ...	12/13/2011
8067167	Hybrid antibodies Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from a...	11/29/2011
7927817	Hybrid antibodies Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from a...	04/19/2011
7915000	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Small animal models for assessing immunomodulatory effects of compounds are provided. ...	03/29/2011
RE42130	Phagemid vectors Phagemid vectors containing a sequence of features between a Col E1 origin and an f1 origin are useful for display of polypeptides or proteins, including antibody libraries. ...	02/08/2011
RE41365	Nested oligonucleotides containing a hairpin for nucleic acid amplification Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered...	06/01/2010
7714110	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-de...	05/11/2010
7598353	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-de...	10/06/2009
7598030	Antibodies against cancer produced using masked cancer cells as immunogen This disclosure relates to methods for selecting antibodies having desirable characteristics from a population of diverse antibodies. More specifically, this disclosure provides methods for identifying antibodies which bind to cancer cells, but which do not bind to ...	10/06/2009
7482435	Rationally designed antibodies Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association wit...	01/27/2009
7435412	Chronic lymphocytic leukemia cell line The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are usefu...	10/14/2008
7427665	Chronic lymphocytic leukemia cell line A CLL line, CLL-AAT, and the preparation and characterization of antibodies using said cell line is disclosed. ...	09/23/2008
7414111	Engineered templates and their use in single primer amplification Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synt...	08/19/2008
7408041	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-de...	08/05/2008
7405279	Chimeric proteins for diagnosis and treatment of diabetes Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins...	07/29/2008
7399594	Hybrid antibodies Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from a...	07/15/2008
7396917	Rationally designed antibodies Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities. ...	07/08/2008
7393648	Hybrid antibodies Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from a...	07/01/2008
7384915	Chimeric insulin-gad proteins for treating patients with type 1 diabetes or at risk of developing type 1 diabetes Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins...	06/10/2008
7361339	Methods for reducing morality associated with acute myocardial infarction Methods of reducing mortality in myocardial infarction patients receiving a stent in connection with percutaneous transluminal coronary angioplasty include administering an anti-inflammatory compound to the patient. In one embodiment, the anti-inflammatory compound ...	04/22/2008
7306906	Engineered templates and their use in single primer amplification Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synt...	12/11/2007
7279158	Methods for the treatment of inflammatory joint disease The use of compounds that block complement component C5 or its active fragments C5a and/or C5b (such compounds collectively referred to as “C5 blockers”) to treat established joint inflammation (arthritis) is disclosed. Administration of such C5 bl...	10/09/2007
7041503	Modified myelin basic protein molecules Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and poly...	05/09/2006
6982323	Chimeric proteins for diagnosis and treatment of diabetes Novel chimeric fusion proteins comprising immunodominant epitopes of GAD and insulin are provided. Also provided are immunomodulatory methods for the use of such proteins for both the prevention and treatment of Type 1 diabetes mellitus. The chimeric fusion proteins...	01/03/2006
6919189	Nested oligonucleotides containing a hairpin for nucleic acid amplification Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered...	07/19/2005
6803230	Phagemid vectors Phagemid vectors containing a sequence of features between a Col E1 origin and an f1 origin are useful for display of polypeptides or proteins, including antibody libraries. ...	10/12/2004
6498285	Methods for producing transgenic pigs by microinjecting a blastomere A transgenic large mammal is produced by a method including the steps of obtaining one or more early embryos, selectively preparing an embryo having at least three cells, and preferably at a stage in development corresponding in time to the onset of trans...	12/24/2002
6355245	C5-specific antibodies for the treatment of inflammatory diseases The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other path...	03/12/2002
6338820	Apparatus for performing assays at reaction sites An apparatus for performing a assays includes an axially rotatable substrate including a plurality of layers of a semiconductor material and numerous radially-arrayed reaction sites. The apparatus further includes a rotary stepper motor which rotates the ...	01/15/2002

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Alexion Pharmaceuticals, Inc.